POSSIBLE CARBAMAZEPINE TOXICITY WITH TERBINAFINE

Main Article Content

Navdeep S Baath
Creighton University Department of Psychiatry, Omaha NE

Jennifer Hong
Creighton University Department of Psychiatry, Omaha NE

S Pirzada Sattar
1 Creighton University Department of Psychiatry, Omaha NE, 2Omaha Veterans Affairs Medical Center (VAMC), Omaha, NE, 3Sanford School of Medicine, University of South Dakota & Avera McKennan Research Institute, Sioux Falls, SD.

Keywords

Terbinafine, carbamazepine drug-drug interaction

Abstract

Objective


To report a case of carbamazepine and terbinafine interaction resulting in an elevated level of carbamazepine and associated symptoms of toxicity.


 


Case summary


A 50-year-old Caucasian man developed an elevated carbamazapine level after starting terbinafine, which caused symptoms of toxicity with gait ataxia, dizziness and falls.


 


Discussion


This is a first report of a drug-drug interaction between carbamazapine and terbinafine. Although the mechanism for this interaction is not fully known, it  is suspected that terbinafine decreased the metabolism of carbamazapine and led to increased levels that continued even days after the carbamazapine had been stopped. The Naranjo Scale suggests that this was a probable interaction (score 6).


 


Conclusions


While several drug-drug interactions have been reported with carbamazapine, there are no previous reports of its interaction with terbinafine. Prescribers should exercise caution when prescribing these medications together.

Abstract 662 | PDF Downloads 210

References

1. Gibaldi M, Levy G. Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetics characteristics. J.Pharm.Sci. 1972. 61, 567-569.
2. Wagner JG. Relations between drug concentration and response. J. Mond. Pharm. 1971. 4, 279-310.
3. http://www.nlm.nih.gov/medlineplus/drugi nfo/uspdi/202111.html (Last accessed on 8-03-05).
4. Diagnostic and Statistical manual of psychiatric disorders. 4th Edition. Washington, DC; American Psychiatric Association, 1994.
5. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998. 39 Suppl 7:S3-7.
6. Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: Gilman AG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological basis for therapeutics. New York: Macillan, 1985:446-72.
7. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry. 1980. 137:782-90.
8. http://www.pharma.us.novartis.com/produc t/pi//pdf/tegretol.pdf (Last accessed 8-03-05).
9. http://www.rxlist.com/cgi/generic/terbin_cp.htm (Last accessed 8-03-05).
10. http://www.rxmed.com/b.main/b2.pharmaceutica l/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LAMISIL.html (Last accessed on 8-03-05)
11. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Carbamazepine pharmacokinetics in obese and lean subjects. The Annals of Pharmacotherapy. 1995. 29(9):843-847.12. Naranjo CA, Busto U, Sellers EM et al. A
12. method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981. 30:239–45.

Article Sidebar

PDF
Published
Dec 8, 2018

Article Details

How to Cite
S Baath, N., Hong, J., & Sattar, S. P. (2018). POSSIBLE CARBAMAZEPINE TOXICITY WITH TERBINAFINE. Journal of Population Therapeutics and Clinical Pharmacology, 13(2). Retrieved from https://jptcp.com/index.php/jptcp/article/view/124
Issue
Vol. 13 No. 2 (2006)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles published in JPTCP  are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.